Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment

Documenti analoghi

• Exploring the role of oxidative stress and the effect of N‐acetylcysteine in thiopurine‐induced liver injury in inflammatory bowel disease: A randomized crossover pilot study
  di: Dirk P. van Asseldonk, et al.
  Pubblicazione: (2024)
• Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
  di: Abhinav Vasudevan, et al.
  Pubblicazione: (2024)
• The fate of thiopurine metabolites after switching to low‐dose thiopurine with allopurinol or thioguanine in IBD patients: A retrospective analysis
  di: Ahmed B. Bayoumy, et al.
  Pubblicazione: (2025)
• Virtual multidisciplinary thiopurine monitoring: experiences from an Australian tertiary inflammatory bowel disease service
  di: Vinny Ea, et al.
  Pubblicazione: (2026)
• Wake up and smell the coffee: The potential of faecal volatile organic compounds in paediatric inflammatory bowel disease
  di: Eva Vermeer, et al.
  Pubblicazione: (2024)